Grifols stock

GRF · BME · EUR

€11.66Change from previous close: +0.04%Absolute change: +€0.00

Close · November 16, 2026

Price history

+10.11% over the period

1 year: from €10.59 (November 17, 2025) to €11.66 (November 16, 2026), +10.11%.

Show chart data

Closing prices adjusted for splits: the last close of each month.

DateClose
November 16, 2026€11.66
October 30, 2026€10.98
September 30, 2026€9.55
August 31, 2026€9.83
July 31, 2026€9.96
June 30, 2026€8.96
May 29, 2026€9.28
April 30, 2026€8.96
March 31, 2026€8.96
February 27, 2026€10.63
January 30, 2026€10.79
December 31, 2025€10.70
November 28, 2025€10.53
November 17, 2025€10.59

At a glance

  • The company

    Research, develop, produce and market plasma-derived medicines and diagnostic testing solutions for healthcare

  • Latest results

    Quarter to June 30, 2026 · EPS €0.22 (estimate €0.24)

TickerLandia's take on Grifols

Analysis calculated by TickerLandia from financial statements and prices, with public rules. Not investment advice. How we analyse stocks

Where the price stands

52-wk low€8.43
52-wk high€11.71

−0.43% from the 52-week high

Analysts · 11 analysts

Average target€15.25+30.88% vs. price

Buy 8 · Hold 2 · Sell 1 · Buy

TickerLandia Fingerprint: Grifols

Compared with similar companies: very low dividend, very low profitability, and very low price.

Financials and price compared with 25 companies in the drug manufacturers - general industry, worldwide. Momentum and risk compared with 1,160 European stocks.

Position in the group from 0 to 100 (100 = highest value): it describes, it does not rate. Tap a row for the metrics. Calculated on November 16, 2026. An indicator calculated by TickerLandia from financial statements and market data. How it is calculated

Valuation

Grifols is cheaper than in the past and cheaper than similar companies

On the latest fiscal year's earnings (2025), Grifols's P/E today is 19.8, below the median of its last 10 fiscal years (30.5; between 18.1 and 257.6 from 2016 to 2025). Grifols's P/E (trailing 12 months): 16.4, −24% against the median of a group of 10 similar companies (21.5).

P/E compared with its history

Compared with 10 similar companies

Grifols's metrics compared with similar companies
MetricGrifolsPosition in the groupBand
P/E (trailing 12 months)16.4Low
Forward P/E10.7Low
Operating margin18.9%Low
ROE7.3%Low
Debt/equity1.12Middle

P/E at fiscal year end; today on the latest fiscal year's earnings. Grey band: the middle half of the group; tick: the median; dot: Grifols. All multiples and dividends

TickerLandia analysisHow it is calculated

The financials

The business in numbers

Revenue

€1.87B

Latest quarter · Q2 2026

Net income

€154M

Latest quarter · Q2 2026

Quarterly net margin

8.2%

Latest quarter · Q2 2026

Numbers and valuation

Full valuation
Market cap
€7.93B
P/E
16.4
EPS
€0.71
Volume
1.27M
Daily trading
€21.5M
Dividend yield
0.71%

How Grifols is changing

All results
  • Revenue grew 7.1% a year on average over the last 5 years

  • Operating margin rose from 11.1% to 18.5%

  • Revenue has grown for 4 fiscal years in a row

Returns

Grifols returns with dividends

€1,000 invested in Grifols 5 years ago, on November 16, 2021, would be worth €651 today with dividends reinvested: −34.91% in total, −8.23% per year. On price alone it would be €637 (−36.26%).

PeriodGrifolsIBEX 35€1,000 becomes
1 month+14.49%+4.21%€1,145
6 months+28.19%+13.60%€1,282
Year to date+8.93%+15.67%€1,089
1 year+11.12%+23.79%€1,111
3 years−6.36%+107.09%€936
5 years−34.91%+121.46%€651
10 years−31.24%+131.75%€688

Over the last 6 months it has done better than 47% of the stocks in the Healthcare sector.

From 1 year up with dividends reinvested, before taxes; under a year price only. IBEX 35: price only. Calculate your investment

The chart in detail

Grifols: technical analysis

Grifols is in an uptrend: the price is above its 50- and 200-session moving averages, and the 200-session average is rising. The price is 65.9% below its all-time closing high (€34.19, February 21, 2020).

Trend
Upward
RSI (14 sessions)
81
Above 70: a strong rise in a short time
vs 200-session average
+19.77%

Active signals

  • New 52-week high.

  • RSI above 70: the stock has risen a lot in a short time.

    since October 30, 2026

Support and resistance

Price areas where Grifols has stopped several times in the last year. They describe the chart; they are not forecasts.

  1. No resistance above: the price is near the highs of the year
  2. Last price€11.66
  3. Support€10.57−9.33%2 touches, last on February 6, 2026
  4. Support€10.17−12.76%3 touches, last on September 3, 2026
  5. Support€9.60−17.64%5 touches, last on September 15, 2026

Volatility and risk

Over the last year it has moved less than the IBEX 35.

Beta (1 year) vs IBEX 35
0.68
Volatility (60 sessions, annualised)
23.2%
Largest fall in the last year
−25.77%

In session, November 16, 2026. Descriptive data calculated on daily prices: it describes the chart and is not investment advice. Beta and volatility describe the last year and can change a lot from one year to the next. How we calculate it

Grifols: seasonality

Average monthly price change over 21 years

+1.0%Jan−0.0%Feb−0.0%Mar+3.0%Apr+3.6%May+1.4%Jun+3.9%Jul−2.6%Aug+0.7%Sep+0.1%Oct−1.9%Nov+3.8%Dec

Over the last 21 years, the strongest month for Grifols has been July: +3.89% on average, positive in 12 years out of 21. The weakest has been August: −2.62% on average, positive in 5 years out of 21. November, the current month, has been positive in 10 years out of 20 (−1.91% on average).

Show chart data
MonthAverageMedianPositive years
January+0.97%+3.37%12 of 20
February−0.05%−0.45%10 of 20
March−0.01%+3.14%12 of 20
April+2.95%+1.32%14 of 20
May+3.61%+3.04%13 of 20
June+1.44%−0.19%10 of 21
July+3.89%+1.47%12 of 21
August−2.62%−3.16%5 of 21
September+0.70%+1.00%12 of 21
October+0.12%+0.20%11 of 21
November−1.91%−0.24%10 of 20
December+3.82%+2.68%14 of 20

Price change only, dividends excluded. Past seasonality does not predict future moves.

The company

Grifols and its competitors

Based in Barcelona, Grifols has been in operation since 1909. The company researches, develops, produces and markets plasma-derived medicines, including albumin, immunoglobulins and thrombin sold to pharma and biotech companies, along with diagnostic testing equipment and reagents, transfusion medicine and clinical diagnostics. Its hospital offering covers intravenous solutions, clinical nutrition, hospital automation systems and medical devices for areas such as interventional neuroradiology, hemodynamics and cardiovascular surgery.

Headquarters
Barcelona, Spain
Employees
25,000
Founded
1909
Chief executive
Jose Ignacio Abia Buenache
Grifols and its competitors
CompanyMarket capOperating marginP/E (trailing 12 months)6 months
GrifolsGRF$8.76B18.9%16.4+28.19%
RecordatiREC$12.11B32.6%21.0+2.62%
OrionORNAV$15.93B38.1%22.0+52.14%
VirbacVIRP$3.28B15.8%19.1+2.00%
BayerBAYN$61.37B16.5%—+51.26%
GSKGSK$101.36B30.5%17.9+3.57%

Same industry or related industries, similar size. Compare Grifols with its competitors · Full profile